Clinical Trial Update: Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the combination of cetuximab and nivolumab in recurrent or metastatic head and neck squamous cell carcinoma has completed, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of the Hypopharynx
• Squamous Cell Carcinoma of the Larynx
• Squamous Cell Carcinoma of the Oral Cavity
• Squamous Cell Carcinoma of the Oropharynx
• Squamous Cell Carcinoma of the Paranasal Sinus

Drugs mentioned

• Cetuximab (Erbitux) (Cetuximab)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-20